{"id":"https://openalex.org/W7161970582","doi":"https://doi.org/10.1093/infdis/jiag269","title":"Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19","display_name":"Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19","publication_year":2026,"publication_date":"2026-05-20","ids":{"openalex":"https://openalex.org/W7161970582","doi":"https://doi.org/10.1093/infdis/jiag269","pmid":"https://pubmed.ncbi.nlm.nih.gov/42165235"},"language":"en","primary_location":{"id":"doi:10.1093/infdis/jiag269","doi":"https://doi.org/10.1093/infdis/jiag269","is_oa":true,"landing_page_url":"https://doi.org/10.1093/infdis/jiag269","pdf_url":null,"source":{"id":"https://openalex.org/S54542293","display_name":"The Journal of Infectious Diseases","issn_l":"0022-1899","issn":["0022-1899","1537-6613"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1093/infdis/jiag269","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044627377","display_name":"Kristin M. Narayan","orcid":"https://orcid.org/0000-0002-7977-4783","observed_orcids":["https://orcid.org/0000-0002-7977-4783"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Kristin Narayan","raw_affiliation_strings":["Invivyd, Inc. , New Haven, Connecticut ,"],"raw_orcid":"https://orcid.org/0000-0002-7977-4783","affiliations":[{"raw_affiliation_string":"Invivyd, Inc. , New Haven, Connecticut ,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114057705","display_name":"Kazima Tosh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kazima Tosh","raw_affiliation_strings":["Invivyd, Inc. , New Haven, Connecticut ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Invivyd, Inc. , New Haven, Connecticut ,","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Anna Holmes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Holmes","raw_affiliation_strings":["Invivyd, Inc. , New Haven, Connecticut ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Invivyd, Inc. , New Haven, Connecticut ,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110274865","display_name":"Leijun Hu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leijun Hu","raw_affiliation_strings":["LH Pharmaceutical Consulting, LLC , Carmel, Indiana ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LH Pharmaceutical Consulting, LLC , Carmel, Indiana ,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136726647","display_name":"Sandeep Reddya Dkottam","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandeep Reddy Dkottam","raw_affiliation_strings":["Invivyd, Inc. , New Haven, Connecticut ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Invivyd, Inc. , New Haven, Connecticut ,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042148787","display_name":"Ilker Yalcin","orcid":"https://orcid.org/0000-0002-4935-9247","observed_orcids":["https://orcid.org/0000-0002-4935-9247"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ilker Yalcin","raw_affiliation_strings":["Invivyd, Inc. , New Haven, Connecticut ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Invivyd, Inc. , New Haven, Connecticut ,","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108778022","display_name":"Mark A. Wingertzahn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Mark Wingertzahn","raw_affiliation_strings":["Invivyd, Inc. , New Haven, Connecticut ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Invivyd, Inc. , New Haven, Connecticut ,","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5044627377","https://openalex.org/A5108778022"],"corresponding_institution_ids":[],"apc_list":{"value":4763,"currency":"USD","value_usd":4763},"apc_paid":{"value":4763,"currency":"USD","value_usd":4763},"fwci":4.5866,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.93615158,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"234","issue":"4","first_page":"e859","last_page":"e868"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10041","display_name":"COVID-19 Clinical Research Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10410","display_name":"COVID-19 epidemiological studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2611","display_name":"Modeling and Simulation"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/covid-19-prevention","display_name":"COVID-19 prevention","score":0.8849999904632568},{"id":"https://openalex.org/keywords/sars-cov-2","display_name":"SARS-CoV-2","score":0.8460000157356262},{"id":"https://openalex.org/keywords/virus-neutralizing-antibodies","display_name":"virus-neutralizing antibodies","score":0.7820000052452087},{"id":"https://openalex.org/keywords/immunocompromised-patients","display_name":"immunocompromised patients","score":0.7929999828338623},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.699999988079071},{"id":"https://openalex.org/keywords/xbb-1-5-variant","display_name":"XBB.1.5 variant","score":0.8460000157356262},{"id":"https://openalex.org/keywords/delta-variant","display_name":"Delta variant","score":0.8579999804496765},{"id":"https://openalex.org/keywords/cross-protection","display_name":"cross-protection","score":0.7360000014305115}],"concepts":[{"id":"https://openalex.org/C32611913","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Titer","level":3,"score":0.7972000241279602},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7807999849319458},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5771999955177307},{"id":"https://openalex.org/C22889606","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Antibody titer","level":4,"score":0.5547999739646912},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5376999974250793},{"id":"https://openalex.org/C138894074","wikidata":"https://www.wikidata.org/wiki/Q7201694","display_name":"Plaque reduction neutralization test","level":4,"score":0.5336999893188477},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5095999836921692},{"id":"https://openalex.org/C14086860","wikidata":"https://www.wikidata.org/wiki/Q337120","display_name":"Neutralization","level":3,"score":0.4542999863624573},{"id":"https://openalex.org/C2779261636","wikidata":"https://www.wikidata.org/wiki/Q7003054","display_name":"Neutralizing antibody","level":3,"score":0.43970000743865967},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4194999933242798},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41350001096725464},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36559998989105225},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.36149999499320984},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.3025999963283539},{"id":"https://openalex.org/C61470247","wikidata":"https://www.wikidata.org/wiki/Q7229825","display_name":"Population study","level":3,"score":0.2831000089645386},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.2815999984741211},{"id":"https://openalex.org/C68443243","wikidata":"https://www.wikidata.org/wiki/Q2786686","display_name":"Quartile","level":3,"score":0.2635999917984009},{"id":"https://openalex.org/C3018913218","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody response","level":3,"score":0.25529998540878296}],"mesh":[{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D000086402","descriptor_name":"SARS-CoV-2","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000086402","descriptor_name":"SARS-CoV-2","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000086402","descriptor_name":"SARS-CoV-2","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000093485","descriptor_name":"COVID-19 Drug Treatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000093485","descriptor_name":"COVID-19 Drug Treatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000093485","descriptor_name":"COVID-19 Drug Treatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000098485","descriptor_name":"Emergency Use Authorization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000098485","descriptor_name":"Emergency Use Authorization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000098485","descriptor_name":"Emergency Use Authorization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000914","descriptor_name":"Antibodies, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000914","descriptor_name":"Antibodies, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000914","descriptor_name":"Antibodies, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016867","descriptor_name":"Immunocompromised Host","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016867","descriptor_name":"Immunocompromised Host","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016867","descriptor_name":"Immunocompromised Host","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057134","descriptor_name":"Antibodies, Neutralizing","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D057134","descriptor_name":"Antibodies, Neutralizing","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D057134","descriptor_name":"Antibodies, Neutralizing","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1093/infdis/jiag269","doi":"https://doi.org/10.1093/infdis/jiag269","is_oa":true,"landing_page_url":"https://doi.org/10.1093/infdis/jiag269","pdf_url":null,"source":{"id":"https://openalex.org/S54542293","display_name":"The Journal of Infectious Diseases","issn_l":"0022-1899","issn":["0022-1899","1537-6613"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Infectious Diseases","raw_type":"journal-article"},{"id":"pmid:42165235","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42165235","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of infectious diseases","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13668337","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13668337/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13668337/pdf/jiag269.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"J Infect Dis","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/infdis/jiag269","doi":"https://doi.org/10.1093/infdis/jiag269","is_oa":true,"landing_page_url":"https://doi.org/10.1093/infdis/jiag269","pdf_url":null,"source":{"id":"https://openalex.org/S54542293","display_name":"The Journal of Infectious Diseases","issn_l":"0022-1899","issn":["0022-1899","1537-6613"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8366649746894836}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W2511883439","https://openalex.org/W3043192034","https://openalex.org/W3163785571","https://openalex.org/W3194402687","https://openalex.org/W4224289402","https://openalex.org/W4226023532","https://openalex.org/W4283808736","https://openalex.org/W4284889304","https://openalex.org/W4313427322","https://openalex.org/W4317870853","https://openalex.org/W4353040051","https://openalex.org/W4366982832","https://openalex.org/W4381050963","https://openalex.org/W4383873186","https://openalex.org/W4385345323","https://openalex.org/W4389031330","https://openalex.org/W4390546146","https://openalex.org/W4391776402","https://openalex.org/W4391934251","https://openalex.org/W4392802952","https://openalex.org/W4394692264","https://openalex.org/W4399694077","https://openalex.org/W4403098436","https://openalex.org/W4404310655","https://openalex.org/W4407895700","https://openalex.org/W4408020406","https://openalex.org/W4410634393","https://openalex.org/W4410760010","https://openalex.org/W4416725282"],"related_works":[],"abstract_inverted_index":{"BACKGROUND:":[0],"Pemivibart":[1,182],"received":[2,88,106],"emergency":[3],"use":[4],"authorization":[5],"for":[6],"COVID-19":[7],"prevention":[8],"in":[9,46,61,142,194,241],"certain":[10],"individuals":[11,242],"with":[12,79,191,204,243],"immunocompromise":[13,87],"based":[14],"on":[15],"immunobridging":[16],"calculated":[17,131],"serum":[18,133],"virus-neutralizing":[19],"antibody":[20],"(csVNA)":[21],"titers.":[22],"We":[23],"report":[24],"an":[25],"analysis":[26],"of":[27,44,111],"measured":[28],"(msVNA)":[29],"titers":[30,60,119,129,153,171,200,206,236,249],"against":[31,175,189,237],"severe":[32],"acute":[33],"respiratory":[34],"syndrome":[35],"coronavirus":[36],"2":[37,62,89],"(SARS-CoV-2)":[38],"variants":[39,226],"before":[40],"and":[41,52,58,179,230,244,259],"after":[42],"receipt":[43],"pemivibart":[45,92,112,134,233],"a":[47,107,123],"SARS-CoV-2":[48,124,240],"immune-experienced":[49],"population":[50],"(CANOPY)":[51],"compare":[53],"the":[54,73,100,156,184],"relationship":[55],"between":[56],"csVNA":[57,128,199,248],"msVNA":[59,118,150,170,186,205],"clinical":[63],"trials.":[64],"METHODS:":[65],"The":[66],"trials":[67],"were":[68,120,130,161,172,201],"conducted":[69],"during":[70],"2023-2024.":[71],"In":[72,99,147],"phase":[74,101],"3":[75],"CANOPY":[76],"trial,":[77,103],"participants":[78],"(cohort":[80,84],"A)":[81],"or":[82,93,115],"without":[83,245],"B)":[85],"significant":[86],"intravenous":[90,109],"4500-mg":[91],"placebo":[94],"infusions":[95],"90":[96],"days":[97],"apart.":[98],"1":[102],"healthy":[104],"adults":[105],"single":[108],"dose":[110],"(1500,":[113],"2500,":[114],"4500":[116],"mg).":[117],"determined":[121],"using":[122],"spike":[125],"pseudotyped":[126],"assay;":[127],"as":[132],"concentrations":[135],"divided":[136],"by":[137],"variant-specific":[138],"IC50":[139],"values":[140],"from":[141],"vitro":[143],"neutralization":[144,253],"assays.":[145],"RESULTS:":[146],"CANOPY,":[148],"predose":[149],"geometric":[151],"mean":[152],"(GMTs)":[154],"to":[155,223],"dominant":[157],"circulating":[158,239],"XBB.1.5":[159],"lineage":[160],"low":[162],"across":[163],"cohorts":[164],"(range,":[165],"78.6-119.8),":[166],"suggesting":[167],"inadequate":[168],"protection.":[169],"substantially":[173],"higher":[174],"earlier":[176,224],"Delta":[177],"(B.1.617.2)":[178],"BA.4/5":[180],"variants.":[181],"increased":[183,234],"day-28":[185],"GMT":[187],">55-fold":[188],"XBB.1.5,":[190],"similar":[192],"levels":[193],"both":[195],"cohorts.":[196],"Across":[197],"trials,":[198],"significantly":[202],"correlated":[203],"(all":[207],"Spearman":[208],"correlation":[209],"coefficients":[210],"\u22650.73,":[211],"P":[212],"<":[213],".0001).":[214],"CONCLUSIONS:":[215],"These":[216],"data":[217],"show":[218],"that":[219,232],"previous":[220],"immune":[221],"experience":[222],"pandemic":[225],"provided":[227],"limited":[228],"cross-protection":[229],"demonstrate":[231],"protective":[235],"newly":[238],"immunocompromise.":[246],"Notably,":[247],"effectively":[250],"predicted":[251],"pemivibart's":[252],"potential.":[254],"Clinical":[255],"Trials":[256],"Registration.":[257],"NCT06039449":[258],"NCT05791318.":[260]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-21T09:56:26.102985","created_date":"2026-05-22T00:00:00"}